Molecular evolution of plasminogen activator inhibitor-1 functional stability (original) (raw)

Abstract

Plasminogen activator inhibitor-1 (PAI-1) is a member of the serine protease inhibitor (serpin) supergene family and a central regulatory protein in the blood coagulation system. PAI-1 is unique among serpins in exhibiting distinct active and inactive (latent) conformations in vivo. Though the structure of latent PAI-1 was recently solved, the structure of the short-lived, active form of PAI-1 is not known. In order to probe the structural basis for this unique conformational change, a randomly mutated recombinant PAI-1 expression library was constructed in bacteriophage and screened for increased functional stability. Fourteen unique clones were selected, and shown to exhibit functional half-lives (T1/2S) exceeding that of wild-type PAI-1 by up to 72-fold. The most stable variant (T1/2 = 145 h) contained four mutations. Detailed analysis of these four mutations, individually and in combination, demonstrated that the markedly enhanced functional stability of the parent compound mutant required contributions from all four substitutions, with no individual T1/2 exceeding 6.6 h. The functional stability of at least eight of the remaining 13 compound mutants also required interactions between two or more amino acid substitutions, with no single variant increasing the T1/2 by > 10-fold. The nature of the identified mutations implies that the unique instability of the PAI-1 active conformation evolved through global changes in protein packing and suggest a selective advantage for transient inhibitor function.

2969

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cadwell R. C., Joyce G. F. Randomization of genes by PCR mutagenesis. PCR Methods Appl. 1992 Aug;2(1):28–33. doi: 10.1101/gr.2.1.28. [DOI] [PubMed] [Google Scholar]
  2. Carmeliet P., Schoonjans L., Kieckens L., Ream B., Degen J., Bronson R., De Vos R., van den Oord J. J., Collen D., Mulligan R. C. Physiological consequences of loss of plasminogen activator gene function in mice. Nature. 1994 Mar 31;368(6470):419–424. doi: 10.1038/368419a0. [DOI] [PubMed] [Google Scholar]
  3. Carmeliet P., Stassen J. M., Schoonjans L., Ream B., van den Oord J. J., De Mol M., Mulligan R. C., Collen D. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest. 1993 Dec;92(6):2756–2760. doi: 10.1172/JCI116893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Carrell R. W., Evans D. L., Stein P. E. Mobile reactive centre of serpins and the control of thrombosis. Nature. 1991 Oct 10;353(6344):576–578. doi: 10.1038/353576a0. [DOI] [PubMed] [Google Scholar]
  5. Carrell R. W., Stein P. E., Fermi G., Wardell M. R. Biological implications of a 3 A structure of dimeric antithrombin. Structure. 1994 Apr 15;2(4):257–270. doi: 10.1016/s0969-2126(00)00028-9. [DOI] [PubMed] [Google Scholar]
  6. Chen K., Arnold F. H. Tuning the activity of an enzyme for unusual environments: sequential random mutagenesis of subtilisin E for catalysis in dimethylformamide. Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5618–5622. doi: 10.1073/pnas.90.12.5618. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Declerck P. J., De Mol M., Alessi M. C., Baudner S., Pâques E. P., Preissner K. T., Müller-Berghaus G., Collen D. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem. 1988 Oct 25;263(30):15454–15461. [PubMed] [Google Scholar]
  8. Fay W. P., Shapiro A. D., Shih J. L., Schleef R. R., Ginsburg D. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med. 1992 Dec 10;327(24):1729–1733. doi: 10.1056/NEJM199212103272406. [DOI] [PubMed] [Google Scholar]
  9. Flam F. Co-opting a blind watchmaker. Science. 1994 Aug 19;265(5175):1032–1033. doi: 10.1126/science.7520602. [DOI] [PubMed] [Google Scholar]
  10. Kleina L. G., Miller J. H. Genetic studies of the lac repressor. XIII. Extensive amino acid replacements generated by the use of natural and synthetic nonsense suppressors. J Mol Biol. 1990 Mar 20;212(2):295–318. doi: 10.1016/0022-2836(90)90126-7. [DOI] [PubMed] [Google Scholar]
  11. Knowles J. R. Enzyme catalysis: not different, just better. Nature. 1991 Mar 14;350(6314):121–124. doi: 10.1038/350121a0. [DOI] [PubMed] [Google Scholar]
  12. Kwon K. S., Kim J., Shin H. S., Yu M. H. Single amino acid substitutions of alpha 1-antitrypsin that confer enhancement in thermal stability. J Biol Chem. 1994 Apr 1;269(13):9627–9631. [PubMed] [Google Scholar]
  13. Lawrence D. A., Berkenpas M. B., Palaniappan S., Ginsburg D. Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J Biol Chem. 1994 May 27;269(21):15223–15228. [PubMed] [Google Scholar]
  14. Lawrence D. A., Olson S. T., Palaniappan S., Ginsburg D. Engineering plasminogen activator inhibitor 1 mutants with increased functional stability. Biochemistry. 1994 Mar 29;33(12):3643–3648. doi: 10.1021/bi00178a022. [DOI] [PubMed] [Google Scholar]
  15. Lawrence D. A., Olson S. T., Palaniappan S., Ginsburg D. Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition. J Biol Chem. 1994 Nov 4;269(44):27657–27662. [PubMed] [Google Scholar]
  16. Lawrence D. A., Strandberg L., Ericson J., Ny T. Structure-function studies of the SERPIN plasminogen activator inhibitor type 1. Analysis of chimeric strained loop mutants. J Biol Chem. 1990 Nov 25;265(33):20293–20301. [PubMed] [Google Scholar]
  17. Lawrence D., Strandberg L., Grundström T., Ny T. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells. Eur J Biochem. 1989 Dec 22;186(3):523–533. doi: 10.1111/j.1432-1033.1989.tb15238.x. [DOI] [PubMed] [Google Scholar]
  18. Loebermann H., Tokuoka R., Deisenhofer J., Huber R. Human alpha 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J Mol Biol. 1984 Aug 15;177(3):531–557. [PubMed] [Google Scholar]
  19. Matsumura M., Becktel W. J., Matthews B. W. Hydrophobic stabilization in T4 lysozyme determined directly by multiple substitutions of Ile 3. Nature. 1988 Aug 4;334(6181):406–410. doi: 10.1038/334406a0. [DOI] [PubMed] [Google Scholar]
  20. Matthews B. W. Genetic and structural analysis of the protein stability problem. Biochemistry. 1987 Nov 3;26(22):6885–6888. doi: 10.1021/bi00396a001. [DOI] [PubMed] [Google Scholar]
  21. Millar D. S., Wacey A. I., Ribando J., Melissari E., Laursen B., Woods P., Kakkar V. V., Cooper D. N. Three novel missense mutations in the antithrombin III (AT3) gene causing recurrent venous thrombosis. Hum Genet. 1994 Nov;94(5):509–512. doi: 10.1007/BF00211016. [DOI] [PubMed] [Google Scholar]
  22. Mitraki A., Fane B., Haase-Pettingell C., Sturtevant J., King J. Global suppression of protein folding defects and inclusion body formation. Science. 1991 Jul 5;253(5015):54–58. doi: 10.1126/science.1648264. [DOI] [PubMed] [Google Scholar]
  23. Mottonen J., Strand A., Symersky J., Sweet R. M., Danley D. E., Geoghegan K. F., Gerard R. D., Goldsmith E. J. Structural basis of latency in plasminogen activator inhibitor-1. Nature. 1992 Jan 16;355(6357):270–273. doi: 10.1038/355270a0. [DOI] [PubMed] [Google Scholar]
  24. Potempa J., Korzus E., Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem. 1994 Jun 10;269(23):15957–15960. [PubMed] [Google Scholar]
  25. Sandberg W. S., Terwilliger T. C. Engineering multiple properties of a protein by combinatorial mutagenesis. Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8367–8371. doi: 10.1073/pnas.90.18.8367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Schreuder H. A., de Boer B., Dijkema R., Mulders J., Theunissen H. J., Grootenhuis P. D., Hol W. G. The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Nat Struct Biol. 1994 Jan;1(1):48–54. doi: 10.1038/nsb0194-48. [DOI] [PubMed] [Google Scholar]
  27. Schulze A. J., Huber R., Bode W., Engh R. A. Structural aspects of serpin inhibition. FEBS Lett. 1994 May 16;344(2-3):117–124. doi: 10.1016/0014-5793(94)00369-6. [DOI] [PubMed] [Google Scholar]
  28. Sherman P. M., Lawrence D. A., Verhamme I. M., Paielli D., Shore J. D., Ginsburg D. Identification of tissue-type plasminogen activator-specific plasminogen activator inhibitor-1 mutants. Evidence that second sites of interaction contribute to target specificity. J Biol Chem. 1995 Apr 21;270(16):9301–9306. doi: 10.1074/jbc.270.16.9301. [DOI] [PubMed] [Google Scholar]
  29. Sherman P. M., Lawrence D. A., Yang A. Y., Vandenberg E. T., Paielli D., Olson S. T., Shore J. D., Ginsburg D. Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center. J Biol Chem. 1992 Apr 15;267(11):7588–7595. [PubMed] [Google Scholar]
  30. Shoichet B. K., Baase W. A., Kuroki R., Matthews B. W. A relationship between protein stability and protein function. Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):452–456. doi: 10.1073/pnas.92.2.452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Stein P. E., Carrell R. W. What do dysfunctional serpins tell us about molecular mobility and disease? Nat Struct Biol. 1995 Feb;2(2):96–113. doi: 10.1038/nsb0295-96. [DOI] [PubMed] [Google Scholar]
  32. Stein P. E., Leslie A. G., Finch J. T., Turnell W. G., McLaughlin P. J., Carrell R. W. Crystal structure of ovalbumin as a model for the reactive centre of serpins. Nature. 1990 Sep 6;347(6288):99–102. doi: 10.1038/347099a0. [DOI] [PubMed] [Google Scholar]
  33. Stemmer W. P. Rapid evolution of a protein in vitro by DNA shuffling. Nature. 1994 Aug 4;370(6488):389–391. doi: 10.1038/370389a0. [DOI] [PubMed] [Google Scholar]
  34. Vassalli J. D., Pepper M. S. Tumour biology. Membrane proteases in focus. Nature. 1994 Jul 7;370(6484):14–15. doi: 10.1038/370014a0. [DOI] [PubMed] [Google Scholar]
  35. Vassalli J. D., Sappino A. P., Belin D. The plasminogen activator/plasmin system. J Clin Invest. 1991 Oct;88(4):1067–1072. doi: 10.1172/JCI115405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Wei A., Rubin H., Cooperman B. S., Christianson D. W. Crystal structure of an uncleaved serpin reveals the conformation of an inhibitory reactive loop. Nat Struct Biol. 1994 Apr;1(4):251–258. doi: 10.1038/nsb0494-251. [DOI] [PubMed] [Google Scholar]